ArticleCells2025
Bioengineering a Human Dermal Equivalent Using Induced Pluripotent Stem Cell-Derived Fibroblasts to Support the Formation of a Full-Thickness Skin Construct.
Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Skin Organoids in Proteostasis Research: Early Insights into Aging.Biomolecules & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vitro tissue models offer a flexible complementary study system for use alongside in vivo human tissue samples. Achieving accurate in vitro models relies on combining appropriate scaffolds, growth factors and cell populations to recreate human tissue complexity. Balancing a consistent cell supply with the creation of healthy tissue models can be challenging; established cell lines are often cancerous, with altered cellular function compared to healthy populations, and primary cells require repeated isolation, with associated batch-to-batch variation. Pluripotent stem cell-derived populations offer a consistent supply, as well as the ability to model disease phenotypes through cell reprogramming using patient-derived cells. In this study, we have used an induced pluripotent stem cell-derived fibroblast population to develop a dermal equivalent model. These cells form a consistent tissue construct with a structure and composition similar to primary fibroblast controls, which are able to support an overlying epidermis. The resultant full-thickness skin model demonstrates the expression of various key skin-related markers, correctly localised within the organised epidermis, notably improving on previous models of a similar nature. Providing proof of concept using an established in vitro protocol, this study paves the way for future work developing consistent, customised, full-thickness human skin equivalents using iPSC-derived populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.